Ignite Creation Date:
2024-05-05 @ 4:52 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00337376
Status:
TERMINATED
Last Update Posted:
2014-01-14
First Post:
2006-06-13
Brief Title:
A Study of the mTOR Inhibitor Rapamycin Rapamune Sirolimus in Combination With Abraxane in Advanced Solid Cancers
Sponsor:
Yale University
Organization:
Yale University
Study Overview
Official Title:
A Phase I Study of the mTOR Inhibitor Rapamycin Rapamune Sirolimus in Combination With Abraxane Paclitaxel Protein-bound Particles in Advanced Solid Cancers
Status:
TERMINATED
Status Verified Date:
2014-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Rapamycin is a drug that has been approved by the Food and Drug Administration government for use in patients receiving a kidney transplant to prevent the patients body from rejecting the transplanted kidney It has shown antitumor effects in the laboratory but has not been approved at this time for the treatment of cancer Abraxane is a new form of chemotherapy that has been approved by the Food and Drug Administration for the treatment of metastatic breast cancer and is a promising drug that is being evaluated in clinical trials for treatment of other cancers This is a phase I study designed to find out if different doses of Rapamycin when combined with Abraxane are safe and well tolerated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None